Moxonidine is an imidazoline compound which acts on agent including comparative studies with pre-existing I 1 imidazoline 'receptors' in the central nervous system drugs, and adverse effect profile. With a growing numto reduce blood pressure. This novel mechanism of ber of effective antihypertensive agents already availaction is claimed to lead to fewer adverse effects than able to the clinician, it is not yet clear whether moxonidthe older centrally-acting agents such as clonidine. In ine represents a significant advance in hypertension this review we examine the drug's pharmacology, clinimanagement. cal pharmacokinetics, efficacy as an antihypertensive
Introduction
The use of drugs which act in the central nervous system (CNS) to lower blood pressure (BP) is not a new concept. From the shrub Rauwolfia was derived reserpine, one of the first antihypertensive agents which depleted peripheral sympathetic neurones of noradrenaline and also interfered with central monoamine neurotransmission. The ␣ 2 -agonists clonidine and methyldopa (via its metabolite ␣-methylnoradrenaline) followed, and for many years were utilised as effective antihypertensive agents. As newer drugs came along, these centrally-acting drugs fell from favour owing to their adverse effects which included dry mouth, sedation and rebound or overshoot hypertension on cessation of therapy.
It was through experimentation with clonidine and methyldopa that a role of central noradrenergic synapses in BP control was initially suspected. Both drugs reduced the firing of efferent sympathetic neurones from the CNS, and when injected directly into the medulla oblongata or fourth ventricle, produced profound falls in BP at lower doses than would be required systemically. Surprisingly, when more potent ␣ 2 -agonists such as guanabenz were developed it was found that the antihypertensive effect was less pronounced.
Examination of the imidazoline structure of clonidine ( Figure 1 ) and studies with other imidazoline compounds led to the concept of a central non-adre- or binding site. Moxonidine has been developed as a novel centrally-acting antihypertensive which by virtue of its selectivity for the imidazoline receptor, was expected to have fewer ␣ 2 -related adverse effects (sedation and dry mouth). Moxonidine and now licenced and marketed in several European another imidazoline compound, rilmenidine, are countries. In this review we examine the pharmacology of the drug and its clinical efficacy as an antihypertensive.
Pharmacology

Evidence for a central site of action
Moxonidine is an imidazoline compound ( Figure 1 ) which exerts its antihypertensive effect by an action in the CNS. There are several pieces of evidence from animal work which unequivocally demonstrate that the drug has a central site of action. Firstly, in anaesthetised rabbits, there is a 30-fold increase in the dose required intravenously compared to that required intracisternally to produce the same fall in BP. 1 In cats, injection of a single dose of moxonidine into the vertebral artery produced a considerably greater hypotensive effect than the same dose injected into the femoral artery. 1 In addition, moxonidine has no hypotensive effect in pithed rats and in cats following spinal cord transection. 2 The site of action of moxonidine in the CNS is thought to be the rostral ventrolateral medulla Maintenance of arteriolar smooth muscle tone and thus of peripheral resistance is dependent on the ceptor stimulation led to adverse effects such as sedtonic discharge of neurones in this area. 5 The RVLM ation 11 ( Figure 2 ). is also the site of termination of afferent barorecepImidazoline receptor sites have subsequently been tor neurones, and this area orchestrates the reflex demonstrated in several different species and control of BP. Micro-injection of moxonidine into tissues, 12-17 and have been classified into at least the RVLM in rats produces profound falls in BP. 
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It of moxonidine in spontaneously hypertensive rats, should be noted that these receptors have thus far injection of the I 1 receptor antagonist efaroxan into only been defined by radioligand binding studies the RVLM blocks the hypotensive action of moxoniand drug-displacement profiles, and that the actual dine. 3 It is therefore apparent that moxonidine can receptor proteins and second messenger systems lower BP by an action at sites located in the RVLM.
have not been fully identified. 19 Characteristics of the two receptor types are summarised in Table 1 .
Imidazoline receptors
The endogenous ligand for these receptor sites may be agmatine. 20 The existence of imidazoline receptors was first proposed in 1984 following examination of structureactivity relationships of various compounds synthe- hypotensive effects of clonidine, while ␣ 2 -adreno-Pharmacological actions of moxonidine mated at 88% 34 and absorption is unaffected by food. 33 In a study involving 18 healthy male volunMoxonidine is a selective I 1 -receptor agonist with an teers who received an oral dose of 200 g moxonid-I 1 :␣ 2 affinity ratio of 40:1 to 70:1. 21 Through an ine, the peak plasma concentration (C max ) was action in the RVLM, it reduces sympathetic outflow 1.50 ± 0.65 ng/ml, the time to maximum plasma conand lowers peripheral vascular resistence. 22 Haemocentration (T max ) was 0.56 ± 0.28 hours, and the halfdynamic studies have confirmed that BP reduction life (t 1/2 ) 1.98 ± 0.68 hours. 34 The volume of distriis not accompanied by any significant change in bution was calculated after intravenous adminisheart rate or cardiac output. 22 There has been a tration to be 1.83 L/kg with 0.44 L/kg apportioned to suggestion that moxonidine may actually produce a the central compartment. A 14 C radiolabelled study slight rise in cardiac output 23, 24 and there is growing showed only modest metabolism, and excretion of interest in the potentially beneficial neuro-humoral moxonidine and its metabolites is almost entirely by effects of moxonidine in the treatment of cardiac the renal route. 33 While two metabolites were identfailure. The reduction in BP obtained with moxonidified, 4,5-dehydromoxonidine and a guanidine ine is accompanied by a reduction in the plasma levderivative, around 85-90% of the drug is excreted els of adrenaline and noradrenaline, and in plasma unchanged, and the metabolites have less than 10% renin activity. 25 of the antihypertensive potency of the parent drug. As imidazoline receptors are widely distributed
The total clearance following oral administration throughout different tissues, moxonidine may be has been calculated at 12.8 ± 2.5 ml/min/kg expected to have other pharmacological actions (Table 2) . 34 besides BP reduction. Studies in rats have confirmed Multiple oral dosing in normal subjects, with a potent reduction in gastric acid and pepsin pro-200 g of moxonidine twice daily, does not appear duction and protection against gastric mucosal to alter the pharmacokinetics, and drug accumuinjury. 26 Again in rats, moxonidine reduced ischaelation does not occur. 35 In renal impairment, howmia-induced cardiac arrhythmias and dose-depenever, the excretion half-life, C max and area under the dently increased the number of rats that survived curve all rise significantly, the levels being inversely without developing arrhythmias following ligation proportional to the glomerular filtration rate. 25 Close of a coronary artery. 27 This anti-arrhythmic effect is observation has been suggested in these patients, most likely a result of reduced sympathetic outflow with use of lower doses titrated to individual BP as moxonidine does not directly alter cardiac refracresponses. In elderly patients, T max and AUC rise, toriness or ECG intervals. 2 and total clearance falls, although renal clearance Further animal studies have confirmed that like remains unchanged. 33 This is interpreted as being the older centrally-acting agents, moxonidine a result of reduced metabolism in the elderly. The increases sodium excretion and induces a diuresis. 1 changes in the pharmacokinetics of moxonidine By reducing sympathetic tone through a central with advanced age are nevertheless small, and no action, moxonidine lowers plasma renin activity, 25 drug accumulation has been observed if standard and thus would be expected to reduce aldosterone doses are used and the patient's renal function is production. There is also evidence for a peripheral normal. 33 natriuretic action-intrarenal injection of moxonidOnly around 7% of the circulating drug is plasma ine 28 and other I 1 -imidazoline receptor-selective protein-bound. 33 As a consequence, few drug intercompounds 29, 30 in rats induces natriuresis. A study actions would be expected with moxonidine. In in healthy human volunteers, however, revealed no studies in humans, no drug-drug interaction has effect of moxonidine on renal excretory function or been demonstrated between moxonidine and renal haemodynamics. 31 The importance of any digoxin, hydrochlorothiazide or glibenclamide. 33 natriuretic action of moxonidine in its hypotensive effect in humans is thus unclear. New antihypertensive drugs are developed with neutral, or preferably, beneficial metabolic effects. Moxonidine has been shown to significantly reduce The clinical pharmacokinetics of moxonidine have been extensively studied in healthy volunteers and intestinal tract, with absolute bioavailability esti-compared for efficacy and tolerability with enalapril
Clinical studies
in 140 patients over an 8-week period. 42 After a pla-(Results are expressed as mean ± s.d.). Pilot studies cebo run-in period, patients were randomised in a using moxonidine in mild-to-moderate hypertendouble-blind fashion to either placebo, moxonidine sion have suggested that an appropriate starting 200 g once daily or enalapril 5 mg once daily, if dose is 200 g once daily. 36, 37 One of the largest mean DBP was у85 mm Hg as measured by ABPM. initial studies was an open multicentre study, in Drug doses were doubled after a further 2 weeks. A which 141 patients initially received 200 g moxonresponse to therapy was defined as sitting DBP р90 idine after a placebo washout. 38 The dose was mm Hg or a fall in DBP of at least 10 mm Hg. In increased up to a maximum of 800 g if diastolic BP addition, 24-h ABPM allowed measurement of remained above 90 mm Hg. BP fell from 170 ± 13.6/ trough:peak ratios. One hundred and thirty-three 103.2 ± 6.3 mm Hg to 147.5 ± 12.1/88.4 ± 5.9 mm Hg patients completed the study protocol. over a 12-month treatment period in which 58.2%
Response rates were similar in the two treatment of patients were maintained on 200 g/day and arms: 66% with enalapril and 60% with moxonid-37.6% on 400 g/day.
ine, and both drugs were significantly superior to A small single-blind, placebo-controlled, crossplacebo. Twenty-four hour DBP was lowered by over study with 250 g moxonidine once daily, 10.1 ± 9.8 mm Hg wtih moxonidine and by showed average reductions in systolic and diastolic 12.6 ± 10.5 mm Hg with enalapril. A trough to peak BP (SBP/DBP) of 23.1 and 17.5 mm Hg respectratio of 0.73 for moxonidine (0.70 for enalapril) indiively. 25 In a larger double-blind placebo-controlled cates that the drug can effectively be given once study, 39 the effects of moxonidine 200 g twice daily. The commonest adverse effect reported with daily, moxonidine 400 g once daily and placebo moxonidine was dry mouth (5/47), but there were a were compared in 49 patients with mild to moderate similar number of adverse effects reported with both hypertension over a 6-week period. Treatment with moxonidine (36.2%) and enalapril (31.9%). It moxonidine significantly reduced both systolic and should be noted, however, that 28.9% of patients on diastolic BP throughout the 24-h period, and both placebo experienced adverse effects. dosage regimes were equally effective. No significant change in heart rate was detected.
(
ii) Beta-blockers Left ventricular hypertrophy (LVH) is an independent predictor of adverse outcome in patients
A randomised, double-blind, parallel group trial with essential hypertension, through its association compared the antihypertensive efficacy of moxonidwith congestive cardiac failure, myocardial ischaeine with that of atenolol. 43 After a 4-week placebo mia and malignant ventricular arrhythmias. While run-in period, patients were randomised to either no large scale studies have been performed with 200 g moxonidine once daily or 50 mg atenolol moxonidine, a study involving 20 patients utilised once daily if DBP lay within the range 95-105 cardiac magnetic resonance imaging to assess the mm Hg. Over an 8-week treatment phase, doses were ability of moxonidine to induce regression of LVH. 40 doubled if DBP did not fall below 90 mm Hg. The Moxonidine reduced mean interventricular septal treatment phase was then followed by a further 2-thickness from 22.5 mm to 19.1 mm over 6 months, week placebo phase. Seventy-nine patients were with no significant change in ejection fraction. entered in total, 63 entered the treatment phase and Moxonidine has been compared for efficacy and 48 completed the full protocol. BP decreased from tolerability with all major existing classes of antihy-166 ± 10/100 ± 5 to 149 ± 21/90 ± 9 mm Hg in the pertensive agent: moxonidine group and from 169 ± 11/101 ± 6 to 149 ± 21/87 ± 8 mm Hg in the atenolol group. The reduction in BP was not significantly different (i) ACE inhibitors between the two groups, and a similar number of adverse effects were reported in each group: 20.6% A randomised double-blind parallel group study used 24-h ambulatory BP monitoring (ABPM) to with moxonidine and 26.5% with atenolol. This study did not, however, include a placebo group. compare the effects of moxonidine 200 g twice daily with those of captopril 25 mg twice daily in 26 patients with a DBP of 85-105 mm Hg over a 4-(iii) Calcium antagonists week period. 41 In the moxonidine group, mean 24-h ambulatory BP was reduced from a baseline of
In one of the largest double-blind studies to date, Wolf 44 compared moxonidine (200-400 g once 144.6 ± 15.8/91.4 ± 5.4 mm Hg to 139.7 ± 18.5/ 86.8 ± 9.7 mm Hg, and in the captopril group from daily) to sustained-release nifedipine (20-40 mg once daily) in 229 patients over a 6-month period. 146.7 ± 10.6/91.5 ± 4.1 mm Hg to 141.0 ± 13.7/ 87.1 ± 7.1 mm Hg. The fall in BP was mainly attribu-A response was defined as a fall in DBP to Ͻ90 mm Hg or by 10 mm Hg. At the end of the study, table to a fall in daytime pressure and was not significantly different between the two groups. No 81.5% in the moxonidine group and 90.7% in the nifedipine had responded. This difference was not change in heart rate was detected, and no rebound hypertension was seen on withdrawal of either drug. statistically significant. BP fell from 168.4 ± 14.9/ 102.3 ± 7.2 mm Hg to 144.6 ± 18.9/86.0 ± 11.5 Eight of 14 patients on moxonidine reported adverse effects (most commonly nausea) compared with 8 of mm Hg in the moxonidine group, and from 167.6 ± 15.2/102.1 ± 6.5 mm Hg to 139.8 ± 15.4/ 12 on captopril (most commonly dizziness).
In a placebo-controlled study, moxonidine was 83.1 ± 9.1 mm Hg in the nifedipine group. Slightly more patients reported adverse effects in the nifedimales entered this study; single doses of moxonidine 200 g, clonidine 200 g or placebo were given pine group, but it was proposed by the authors that most adverse effects were not likely to be drugin a random order. During the study day, clonidine and moxonidine lowered BP, with a significantly related. Again, no placebo group was included for comparison, and these conclusions remain to be greater reduction achieved with clonidine. No change in heart rate was detected with either drug. confirmed.
Drowsiness and dry mouth were twice as common with clonidine, but equi-effective hypotensive doses (iv) Thiazide diuretics were not being compared. Moxonidine has been studied in combination with thiazide diuretics. In a placebo-controlled double-
Adverse effects
blind parallel group study in 160 patients with mildto-moderate hypertension, the effects of 400 g
The main dose-limiting adverse effects of most centrally-acting antihypertensive agents are sedation moxonidine once daily, hydrochlorothiazide 25 mg once daily, a combination of the two or placebo were and dry mouth. Moxonidine therapy is said to be less frequently associated with these adverse effects. compared. Both moxonidine and hydrochlorothiazide were shown to be equi-effective at reducing BP,
In a double-blind study comparing equipotent antihypertensive doses of moxonidine and clonidine, but the combination was superior with a mean reduction in BP of 27 ± 16/16 ± 7.9 mm Hg. 45 30% of patients experienced side effects with moxonidine compared to 53% with clonidine. 48 Dry mouth and oedema were significantly less common (v) Alpha-blockers with moxonidine, but there was no statistically significant reduction in the reporting of sedation. A An intra-individual study compared the efficacy and tolerability of moxonidine with prazosin. 46 Thirty double-blind crossover study in 20 patients revealed that while clonidine withdrawal was associated patients with mild-to-moderate hypertension were treated with 200-400 g/day moxonidine for 4 with rapid reversal and even overshoot (rebound) hypertension, this was not observed for moxonidine. weeks. This was followed by a wash-out period of 2 weeks, and then a further 4-week treatment period This finding confirms the lack of rebound hypertension seen in animal models with moxonidine. 50 In with prazosin 1-3 mg/day. A similar reduction in BP was obtained with the two drugs, but dose this same study, tiredness was significantly more common with clonidine, and patients reported a titration took longer with prazosin. In addition, the majority of patients were maintained on once-daily general feeling of well-being on moxonidine but not on clonidine. 47 Other reported adverse effects with moxonidine, while the majority on prazosin required three times daily dosing. General wellmoxonidine are sleep disturbance, nausea and dizziness. being was reported as being better with moxonidine, and there were significantly more adverse effects When compared to the four main classes of current antihypertensive agents (ACE inhibitors, with prazosin therapy, the commonest being postural hypotension, tiredness and nervousness. Dry diuretics, calcium antagonists, beta-blockers), overall patient acceptability with moxonidine was at mouth and tiredness were the most frequently reported adverse effects with moxonidine. As yet, least as good 41, 45 if not better. 43, 44 In a total of 970 patients who have received moxonidine in conno comparison has been made with doxazosin.
trolled clinical trials, nine serious adverse events have been documented: six were felt to be unrelated (vi) Clonidine to the drug and three were thought related (cardiac failure, unstable angina and syncope).
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Moxonidine was originally introduced as an alternative to clonidine. The first study to compare the two Standard toxicology studies suggest that moxonidine is devoid of any mutagenic, carcinogenic or drugs was by reported by Plänitz in 1984, 47 where a double-blind crossover design was used. Twenty teratogenic effects. 52 Nevertheless, it is excreted in breast milk and is contraindicated in pregnancy or hypertensive patients were treated with either 200 micrograms of clonidine or moxonidine for 2 weeks, breast-feeding. the dose being increased until DBP was Ͻ90 mm Hg. After 2 weeks, the drugs were switched for a further
Conclusion
2 weeks without a wash-out period. Both drugs were equi-effective at BP reduction, with a mean daily Moxonidine is the first UK-licensed member of a new class of centrally-acting antihypertensive agent, dose of 300 g. Six patients reported adverse effects with moxonidine compared to 17 with clonidine; the I 1 imidazoline receptor agonists. Short and medium-term studies show that the drug is as effecdry mouth and tiredness were the commonest adverse effects.
tive at BP reduction as most of the current antihypertensives on the market. While dry mouth occurs In a further double-blind, parallel-group comparison, moxonidine was again as effective as clonidine in around 10% of patients treated with moxonidine, other adverse effects are considerably less common, at BP reduction, but adverse effects were significantly more common in the clonidine group. 48 and in particular, rebound hypertension, a phenomenon reported after abrupt withdrawal of clonidine A similar crossover study compared haemodynamic and behavioural parameters with clonidine therapy, does not seem to occur. Furthermore, moxonidine causes less sedation than the older cenand moxonidine. fere with the renin angiotensin system or peripheral 19 Bousquet P. Imidazoline receptors: from basic conadrenergic blockers.
cepts to recent developments. J Cardiovasc Pharmacol 1995; 26 (Suppl 2): S1-S6.
